Cell line · CVCL_0093
Papers53
1 to 20 of 53
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Development of CAR T Cells Targeting a Surface RNA-Binding Protein for the Treatment of Acute Leukemias. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RBM15B recognizes H3K79me2 to guide selective m6A-modification of mRNA and enhance oncoprotein translation in MLL-r leukemia. | EMBO J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Chronic ER Stress Triggers Cell-Surface Chaperones as the Therapeutic Targets of CAR Cells in Acute Myeloid Leukemia. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Highly specific Immunoproteasome inhibitor M3258 induces proteotoxic stress and apoptosis in KMT2A::AFF1 driven acute lymphoblastic leukemia. | Sci Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| GREM1 deficiency induced bone marrow adipose niche promotes B-cell acute lymphoblastic leukemia disease progression. | Int J Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway-Deficient Acute Myeloid Leukemia. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| KMT2A degradation is observed in decitabine-responsive acute lymphoblastic leukemia cells. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Novel immunotherapeutics against LGR5 to target multiple cancer types. | EMBO Mol Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Comparable efficacy of oral bendamustine versus intravenous administration in treating hematologic malignancies. | Cancer Chemother Pharmacol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Pharmacological degradation of ATR induces antiproliferative DNA replication stress in leukemic cells. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| DNA-guided transcription factor cooperativity shapes face and limb mesenchyme. | Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators. | Cell Genom | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 37398193 | bioRxiv | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Knockdown of MEF2D inhibits the development and progression of B-cell acute lymphoblastic leukemia. | Transl Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Low Prevalence of ETV6::RUNX1 Fusion Gene in a Hispanic Population. | Front Pediatr | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Hypoxic, glycolytic metabolism is a vulnerability of B-acute lymphoblastic leukemia-initiating cells. | Cell Rep | 2022 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0093/papers